Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anika Therapeutics, Inc.ANIK · Entity 6005 | Director · President and CEO | June 03, 2026 | June 05, 2026 |
| VSE CORPVSEC · Entity 3833 | Senior Vice President and CFO | March 31, 2024 | April 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anika Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,742 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 12,840 · Balance 49,742 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F2: Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 45,973 |
Reported balance
After 2026-06-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-03 · Tax withholding · Disposed 3,769 · Balance 45,973 F3: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 12,840 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Exercise / conversion · Disposed 12,840 · Balance 12,840 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
F2: Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.
F3: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026.
F4: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award.
VSE CORP
Report date March 31, 2024 · Filed April 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.05SEC Table I · non-derivative | Direct | 28,763 |
Ending reported balance
After 2024-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-03-31 · Grant · Acquired 2,567 · Balance 28,636 F1: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2023. Row 2 · 2024-03-31 · Exercise / conversion · Acquired 1,287 · Balance 29,923 F2: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Row 3 · 2024-04-01 · Tax withholding · Disposed 1,160 · Balance 28,763 F3: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2023.
F2: Represents acquisition of shares of VSE common stock upon vesting of RSUs.
F3: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 12,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259520 · ownership.xml · derivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,840 Underlying: Common Stock · 12,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award. F4 · derivative.expiration_date: On June 3, 2024, the Reporting Person was granted 38,520 RSUs vesting in three equal annual installments beginning on June 3, 2025. This transaction reflects the second vesting installment of such RSU award. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 3,769 | $14.41 | $54,311.29 |
DisclosureSEC source: 0001193125-26-259520 · ownership.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,973 F3 · shares: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2026. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 12,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-259520 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes 739 shares acquired on May 14, 2026 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 30, 2026 Filed Apr 30, 2026 21:22 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | PurchaseCommon Stock | 12,200 | $12.29 | $149,880.66 |
DisclosureSEC source: 0001193125-26-197887 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,163 F1 · price: The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.235 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:44 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 12,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111502 · ownership.xml · derivative · entry 4 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,649 Underlying: Common Stock · 12,824 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: On March 14, 2025, the Reporting Person was granted 38,473 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. F4 · derivative.expiration_date: On March 14, 2025, the Reporting Person was granted 38,473 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:44 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 5,944 | $14.20 | $84,404.80 |
DisclosureSEC source: 0001193125-26-111502 · ownership.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,963 F3 · shares: Reflects an aggregate of 5,944 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:44 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 6,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111502 · ownership.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,907 F2 · shares: On March 14, 2025, the Reporting Person was granted 19,236 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:44 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 12,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111502 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 23:45 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 130,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036129 · ownership.xml · derivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,402 Underlying: Common Stock · 130,402 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement. F3 · derivative.exercise_date: Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. F3 · derivative.expiration_date: Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 23:45 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Appreciation Rights · Derivative | 310,207 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001193125-26-036129 · ownership.xml · derivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,207 Underlying: Common Stock · 310,207 shares Expires 2036-02-01 F2 · derivative.exercise_price: The Stock Appreciation Right is payable in cash, shares of common stock, or a combination thereof, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and the applicable award agreement. F3 · derivative.exercise_date: Vests in three equal annual installments, with the first installment vesting on February 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 12,840 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003729 · ownership.xml · derivative · entry 3 Griffin Stephen D. · CIK 0001831125 · EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,680 Underlying: Common Stock · 12,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning June 3, 2025. F5 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning June 3, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 3,769 | $11.59 | $43,682.71 |
DisclosureSEC source: 0001171843-25-003729 · ownership.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,871 F3 · shares: Reflects an aggregate of 3,769 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on June 3, 2025. F4 · price: Reflects the closing price of ANIK common stock on June 3, 2025, the trading date on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:01 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 12,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003729 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · EVP, CFO & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the first vesting installment of RSUs granted on June 3, 2024. F2 · balance_after: Includes 800 shares acquired on May 14, 2025 under the Anika Therapeutics, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 18,672 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001533 · ownership.xml · derivative · entry 2 Griffin Stephen D. · CIK 0001831125 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,672 Underlying: Common Stock · 18,672 shares Expires not disclosed F2 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 18,672 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. F2 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 18,672 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:16 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 38,473 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-001533 · ownership.xml · derivative · entry 1 Griffin Stephen D. · CIK 0001831125 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,473 Underlying: Common Stock · 38,473 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 96,525 | $0.00 Strike: $29.35 | $0.00 |
DisclosureSEC source: 0001171843-24-003314 · ownership.xml · derivative · entry 2 Griffin Stephen D. · CIK 0001831125 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,525 Underlying: Common Stock · 96,525 shares Expires 2034-06-03 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on June 3, 2025. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 38,520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-24-003314 · ownership.xml · derivative · entry 1 Griffin Stephen D. · CIK 0001831125 · EVP, CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,520 Underlying: Common Stock · 38,520 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning June 3, 2025. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning June 3, 2025. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 21:04 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 1,160 | $79.02 | $91,663.20 |
DisclosureSEC source: 0000950170-24-040328 · ownership.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,763 F3 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 21:04 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock, par value $.05 | 1,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040328 · ownership.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 21:04 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 2,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040328 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,636 F1 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2023. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionRestricted Stock Units · Derivative | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · derivative · entry 8 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,324 Underlying: Common Stock · 1,324 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of VSEC common stock. F9 · derivative.exercise_date: These restricted stock units granted on 3/11/2022 vest in three equal annual installments. F9 · derivative.expiration_date: These restricted stock units granted on 3/11/2022 vest in three equal annual installments. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock | 3,031 | $75.12 | $227,688.72 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · nonDerivative · entry 5 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,069 F6 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of the RSUs and PRSUs. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock | 1,821 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · nonDerivative · entry 4 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,100 F5 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 11, 2022 for the performance period ended December 31, 2023. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock | 1,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs that were granted on March 11, 2022. F2 · price: Each restricted stock unit represents a right to receive one share of VSEC common stock. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionRestricted Stock Units · Derivative | 1,832 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · derivative · entry 7 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,666 Underlying: Common Stock · 1,832 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of VSEC common stock. F8 · derivative.exercise_date: These restricted stock units granted on 03/10/2023 vest in three equal annual installments. F8 · derivative.expiration_date: These restricted stock units granted on 03/10/2023 vest in three equal annual installments. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock | 5,132 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,955 F3 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 10, 2023 for the performance period ended December 31, 2023. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock | 1,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs that were granted on March 10, 2023. F2 · price: Each restricted stock unit represents a right to receive one share of VSEC common stock. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 20:13 UTC | VSE CORP VSEC · Entity 3833 | GrantRestricted Stock Units · Derivative | 3,549 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-029945 · ownership.xml · derivative · entry 6 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,549 Underlying: Common Stock · 3,549 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of VSEC common stock. F7 · derivative.exercise_date: These restricted stock units granted on 3/10/2023 vest in three equal annual installments. F7 · derivative.expiration_date: These restricted stock units granted on 3/10/2023 vest in three equal annual installments. Read SEC document |
| December 29, 2023 Filed Jan 2, 2024 21:04 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 233 | $47.12 | $10,977.84 |
DisclosureSEC source: 0000950170-24-000248 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,991 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the VSE Corporation 2021 Employee Stock Purchase Plan. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:20 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 268 | $41.01 | $10,990.14 |
DisclosureSEC source: 0000950170-23-031638 · ownership.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Senior Vice President and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,758 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the VSE Corporation 2021 Employee Stock Purchase Plan. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 814 | $44.90 | $36,548.60 |
DisclosureSEC source: 0000899243-23-010394 · doc4.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,490 F3 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 1,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010394 · doc4.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,304 F2 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2022. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock, par value $.05 | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010394 · doc4.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 947 | $40.95 | $38,779.65 |
DisclosureSEC source: 0000899243-23-008396 · doc4.xml · nonDerivative · entry 5 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 F5 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 1,820 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008396 · doc4.xml · nonDerivative · entry 4 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,547 F4 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 11, 2022 for the performance period ended December 31, 2022. Read SEC document |
| March 11, 2023 Filed Mar 14, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock, par value $.05 | 1,324 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008396 · doc4.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 20 | $42.23 | $844.60 |
DisclosureSEC source: 0000899243-23-008396 · doc4.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,403 F2 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSPs. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:15 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 66 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008396 · doc4.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,423 F1 · shares: Reflects vesting of annual stock-settled dollar-denominated bonus awards (RSP) earned based on prior performance in the year of grant and generally vesting over a three-year service period in three equal tranches. Read SEC document |
| March 10, 2023 Filed Mar 17, 2023 22:32 UTC Amendment | VSE CORP VSEC · Entity 3833 | GrantRestricted Stock Units · Derivative | 5,498 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008974 · doc4a.xml · derivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,498 Underlying: Common Stock, par value $.05 · 5,498 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VSEC common stock. F1 · date: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. F1 · shares: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. F1 · derivative.exercise_date: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. F3 · derivative.exercise_date: The restricted stock units will vest in substantially equal installments on each of the three anniversaries of the grant date. F1 · derivative.expiration_date: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. F3 · derivative.expiration_date: The restricted stock units will vest in substantially equal installments on each of the three anniversaries of the grant date. F1 · derivative.underlying_shares: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. F1 · balance_after: The original Form 4, filed on March 10, 2023, is being amended by this Form to correct a clerical error in the transaction and vesting dates and the number of shares granted. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:15 UTC | VSE CORP VSEC · Entity 3833 | GrantRestricted Stock Units · Derivative | 4,102 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008029 · doc4.xml · derivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,102 Underlying: Common Stock, par value $.05 · 4,102 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VSEC common stock. F2 · derivative.exercise_date: The restricted stock units will generally vest in substantially equal installments on each of March 8, 2024, March 8, 2025 and March 8, 2026. F2 · derivative.expiration_date: The restricted stock units will generally vest in substantially equal installments on each of March 8, 2024, March 8, 2025 and March 8, 2026. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:15 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 141 | $32.31 | $4,556.22 |
DisclosureSEC source: 0000899243-23-000223 · doc4.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,357 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the VSE Corporation 2021 Employee Stock Purchase Plan. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 22:25 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 1,506 | $48.54 | $73,101.24 |
DisclosureSEC source: 0000899243-22-035549 · doc4.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,216 Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 22:25 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-035549 · doc4.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,722 F1 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:30 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 323 | $33.07 | $10,681.74 |
DisclosureSEC source: 0000899243-22-025037 · doc4.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,722 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the VSE Corporation 2021 Employee Stock Purchase Plan. This transaction is exempt under Rule 16b-3(c). Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:48 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 777 | $46.09 | $35,811.93 |
DisclosureSEC source: 0001868979-22-000024 · primary_doc.xml · nonDerivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,399 F3 · shares: Represents withholding of shares of VSE common stock for the tax liability associated with the vesting of RSUs and PRSUs. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:48 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 1,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001868979-22-000024 · primary_doc.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,176 F2 · shares: Represents acquisition of shares of VSE common stock upon vesting of PRSUs that were granted on March 31, 2021 for the performance period ended December 31, 2021. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:48 UTC | VSE CORP VSEC · Entity 3833 | Exercise / conversionCommon Stock, par value $.05 | 1,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001868979-22-000024 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents acquisition of shares of VSE common stock upon vesting of RSUs. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:50 UTC | VSE CORP VSEC · Entity 3833 | GrantRestricted Stock Units · Derivative | 3,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001868979-22-000017 · primary_doc.xml · derivative · entry 3 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,972 Underlying: Common Stock, par value $.05 · 3,972 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VSE Corporation common stock. F3 · derivative.exercise_date: The restricted stock units will generally vest in substantially equal installments on each of March 11, 2023, March 11, 2024 and March 11, 2025. F3 · derivative.expiration_date: The restricted stock units will generally vest in substantially equal installments on each of March 11, 2023, March 11, 2024 and March 11, 2025. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:50 UTC | VSE CORP VSEC · Entity 3833 | Tax withholdingCommon Stock, par value $.05 | 19 | $43.30 | $822.70 |
DisclosureSEC source: 0001868979-22-000017 · primary_doc.xml · nonDerivative · entry 2 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,560 Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 20:50 UTC | VSE CORP VSEC · Entity 3833 | GrantCommon Stock, par value $.05 | 64 | $0.00 | $0.00 |
DisclosureSEC source: 0001868979-22-000017 · primary_doc.xml · nonDerivative · entry 1 Griffin Stephen D. · CIK 0001831125 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,579 F1 · shares: Reflects vesting of annual stock-settled dollar-denominated bonus awards earned based on prior performance in the year of grant and generally vesting over a three-year service period in three equal tranches. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.